

Offices at CHENNAI- COIMBATORE - MUMBAI –BANGALORE

Limited Review Report

Review Report to
The Board of Directors,
MONO PHARMACARE LIMITED

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ('the Statement') of **MONO PHARMACARE LIMITED** ("the Company") for the half year ended September 30, 2025, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The preparation of the Statement is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement of Unaudited Financial Results based on our review.

We conducted our review in accordance with the Standard on Review Engagement-(SRE) 2410, on "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KUMBHAT & CO LLP
Chartered Accountants
Firm Regn. No. S000162/001609S

Gaurang
Champakla
I Unadkat

Digitally signed by
Gaurang Champakla
Unadkat
Date: 2025.11.28
22:36:30 +05'30'

Gaurang C. Unadkat
Partner

Place: Mumbai
Dated: November 28, 2025

Mem.No. 131708
UDIN: 25131708BMIEFG5114

Statement of Standalone Financial Results for the period ended on September 30, 2025

		(Rs. in Lakhs)			
	Particulars	For the Half Year Ended		Year ended on	
		September 30, 2025	March 31, 2025	September 30, 2024	March 31, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from operation	4937.20	3825.77	4438.32	8264.08
II	Other income	1.37	175.18	78.39	253.57
III	Total Revenue (I + II)	4938.57	4000.94	4516.71	8517.65
IV	Expenses				
	Purchase of Traded Goods	4302.92	3783.00	4326.19	8109.19
	(Increase)/Decrease in Stock	321.45	-303.59	-376.13	-679.72
	Employee Benefits Expenses	172.09	147.56	118.74	266.30
	Finance Cost	71.33	64.92	59.34	124.27
	Depreciation and Amortisation Cost	3.89	5.18	3.17	8.36
	Other expenses	65.05	207.06	104.88	311.94
	Total Expenses	4936.73	3904.13	4236.19	8140.33
V	Profit before tax Extraordinary and Exceptional Items (III - IV)	1.85	96.81	280.51	377.32
VI	Exceptional Items	-	-	-	-
VII	Extraordinary Items And Tax (V- VI)	-	-	-	-
VIII	Profit Before Tax	1.85	96.81	280.51	377.32
IX	Tax Expenses				
	(1) Current Tax	0.46	19.60	52.00	71.60
	(2) Deferred Tax	-0.93	-2.52	-0.78	-3.30
X	Profit (Loss) for the Period	2.31	79.73	229.29	309.02
XI	Earning per Equity share :				
	(1) Basic	0.01	0.45	1.30	1.75
	(2) Diluted	0.01	0.45	1.30	1.75

Notes:

1.The above results were reviewed and recommended by the Audit Committee, at its meeting held on **28th November,2025** for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The Statutory Auditors have expressed an unqualified opinion.

2.The Company is listed on the SME platform of the National Stock Exchange of India Limited and the provisions of the IND AS as per rule 4 of the Companies (Indian Accounting Standards) Rules, 2015, Reconciliation of Profit and Loss and Reconciliation of Equity does not apply to the company and hence not reported.

3.Segment Reporting : The company is in the business of distribution of pharmaceutical items. Therefore disclosures under Accounting Standard 17- Primary Segment Reporting is not applicable.Secondary segmental reporting on the basis of the geographical location of the customers is as below :

Sr.No	Particulars	Half year ended on			
		September 30, 2025	March 31, 2025	September 30, 2024	March 31, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	India	4937.20	3825.77	4438.32	8264.08
2	South Asian Countries	-	-	-	-
3	Rest of the World	-	-	-	-
	Total	4937.20	3825.77	4438.32	8264.08

4.The financial Results have been prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.

5. The Company has not paid the Income Tax liabilities of Rs. 43.72 lakhs for A.Y. 2024-2025 and Rs. 83.95 lakhs for 2025-26 of lakhs. However the provision has been made along-with the interest. The management is working on improving the cash flow management to ensure such non-compliance does not occur in future.

6. The above financial results are available on the website of the company i.e. www.monopharmacareltd.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com

7.Figures for previous half year/ year have been regrouped wherever necessary.

For and on behalf of the Board of Directors
Mono Pharmacare Limited.

Panilam S. Laksharaya
Chairman & Managing Director

DIN: 07659275
Date: November 28, 2025
Place: Ahmedabad

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com

Standalone Statement of Assets and Liabilities

(Rs. in Lakhs)

	Particulars	As at September 30th, 2025 (Unaudited)	As at March 31st, 2025 (Audited)
I.	EQUITY AND LIABILITIES		
(1)	Shareholders' Funds		
	(a) Share Capital	1766.86	1766.86
	(b) Reserve and surplus	1355.37	1353.06
		3122.23	3119.92
(2)	Non-current liabilities		
	(a) Long-term borrowings	1459.32	1354.56
	(b) Long-term Provisions	10.55	8.38
		1469.87	1362.94
(3)	Current Liabilities		
	(a) Short Term Borrowings	1070.55	1014.72
	(b) Trade Payables	2613.73	932.29
	(c) Other Current Liabilities	156.60	88.71
	(d) Short-term Provisions	85.28	88.23
		3926.17	2123.95
	TOTAL EQUITY AND LIABILITIES	8518.26	6606.81
II.	ASSETS		
(1)	Non Current Assets		
	(a) Property, Plants & Equipment		
	(i) Tangible Assets	17.76	21.32
	(ii) Intangible Assets	0.87	1.00
	(iii) WIP	1.80	1.80
	(b) Non-Current Investments	1071.38	1083.94
	(c) Deferred tax assets (Net)	5.39	4.47
	(d) Long-term loans and advances	0.75	0.75
		1097.95	1113.27
(2)	Current Assets		
	(a) Inventories	2457.58	2779.03
	(b) Trade Receivables	4614.89	1889.70
	(c) Cash and Cash Equivalents	54.98	11.11
	(d) Short Term Loans and Advances	291.93	768.39
	(e) Other Current Assets	0.92	45.30
		7420.30	5493.54
	TOTAL ASSETS	8518.26	6606.81

For and on behalf of the Board of Directors
Mono Pharmacare Limited


Panilam S. Lakhataria

Chairman & Managing Director

DIN: 07659275

Date: November 28, 2025

Place: Ahmedabad

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007


CIN: U24304GJ2022PLC136193

Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com

Cash Flow statement for the period ended on September 30, 2025**(Rs. in Lakhs)**

Particulars	September 30, 2025	March 31, 2025
Cash flow from operating activities		
Profit/(loss) before tax	1.85	377.32
Non-cash adjustments to reconcile profit before tax to net cash flows		
Depreciation	3.89	8.36
Finance Cost	71.33	124.27
Operating profit/(loss) before working capital changes	77.06	509.95
Movements in working capital:		
Increase/(decrease) in trade payables	1681.44	640.57
Increase/(decrease) in other current liabilities	67.89	9.24
Increase/(decrease) in short term provision	-2.94	61.27
Increase/(decrease) in short term borrowings	55.83	121.26
Decrease/(increase) in Inventories	321.45	-679.72
Decrease/(increase) in trade receivables	-2725.19	-145.49
Decrease/(increase) in short-term loans and advances	476.46	-540.77
Decrease/(increase) in other Current Assets	44.38	22.42
Cash generated from Operations	-3.63	-1.26
Less: Direct taxes paid	-0.46	-71.60
Net Cash from Operating Activities (A)	-4.09	-72.86
Cash flows from investing activities		
Sale/(Purchase) of Fixed Assets	-0.21	-18.18
Purchase of Investment	12.56	-724.45
Net cash flow from/(used in) investing activities (B)	12.35	-742.63
Cash flow from financing activities		
Acceptance / (Repayment) of Long Term Loan	104.76	921.03
Payment / (Repayment) of Long term Loan advance	-	0.70
Long term Provision	2.17	4.09
Proceeds from issue of equity shares	-	-
Securities Premium on Allotment of Equity Shares	-	-
Utilised for IPO Expenses	-	-
Finance Cost	-71.33	-124.27
Net cash flow from/(used in) financing activities (C)	35.60	801.55
Net increase/(decrease) in cash and cash equivalents (A+B+C)	43.86	-13.94
Cash and cash equivalents at the beginning of the year	11.11	25.05
Cash and cash equivalents at the end of the year	54.98	11.11
Net increase/(decrease) in cash and cash equivalents	43.86	-13.94

For and on behalf of the Board of Directors
Mono Pharmacare Limited


Pandam S. Lakhariya
Chairman & Managing Director
DIN: 07659275
Date: November 28, 2025
Place: Ahmedabad

Offices at CHENNAI- COIMBATORE - MUMBAI –BANGALORE

Limited Review Report

Review Report to
The Board of Directors,
MONO PHARMACARE LIMITED

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results ('the Statement') of **MONO PHARMACARE LIMITED** ("the Parent") ("the Company") and its Subsidiary Company for the half year ended September 30, 2025, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The preparation of the Statement is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Consolidated Statement of Unaudited Financial Results based on our review.

We conducted our review in accordance with the Standard on Review Engagement-(SRE) 2410, on "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KUMBHAT & CO LLP
Chartered Accountants
Firm Regn. No. S000162/001609S

Gaurang
Champakl
al Unadkat

Digitally signed by
Gaurang Champakl
Unadkat
Date: 2025.11.28
22:35:54 +05'30'

Gaurang C. Unadkat
Partner

Mem.No. 131708

UDIN: 25131708BMIEFH9692

Place: Mumbai
Dated: November 28, 2025

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin- 380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacare Ltd. com

Email: info@monopharmacare Ltd. com

Statement of Consolidated Financial Results for the period ended ended on September 30, 2025

(Rs. in Lakhs)

	Particulars	For the Half Year Ended		Year ended on	
		September 30, 2025	March 31, 2025	September 30, 2024	March 31, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from operation	6629.12	8118.22	8716.28	16834.49
II	Other income	1.40	93.61	4.27	97.88
III	Total Revenue (I + II)	6630.52	8211.83	8720.55	16932.38
IV	Expenses				
	Purchase of Traded Goods	5800.94	8060.31	8480.82	16541.13
	(Increase)/Decrease in Stock	377.85	-764.30	-545.06	-1309.35
	Employee Benefits Expenses	204.38	208.47	170.21	378.67
	Finance Cost	160.57	246.25	156.31	402.55
	Depreciation and Amortisation Cost	5.79	6.44	6.42	12.87
	Other expenses	68.85	323.58	136.64	460.22
	Total Expenses	6618.38	8080.75	8405.34	16486.08
V	Profit before tax Extraordinary and Exceptional Items (III - IV)	12.14	131.08	315.21	446.29
VI	Exceptional Items	-	-	-	-
VII	Extraordinary Items And Tax (V- VI)	-	-	-	-
	Prior Period Expenses	-	-	-	-
VIII	Profit Before Tax	12.14	131.08	315.21	446.29
IX	Tax Expenses				
	(1) Current Tax	10.88	53.05	85.95	139.00
	(2) Deferred Tax	-0.93	-4.08	0.78	-3.30
X	Profit (Loss) for the Period	2.18	82.11	228.49	310.59
XI	Minority Interest	-0.13	-0.82	-0.75	-1.57
XII	Profit/(Loss) for the year after Taxes and Minority Interest	2.05	81.28	227.74	309.02
XIII	Earning per Equity share :				
	(1) Basic	0.01	0.45	1.30	1.75
	(2) Diluted	0.01	0.45	1.30	1.75

Notes:

1. The above results were reviewed and recommended by the Audit Committee, at its meeting held on **28th November, 2025** for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The Statutory Auditors have expressed an unqualified opinion.

2. The Company is listed on the SME platform of the National Stock Exchange of India Limited and the provisions of the IND AS as per rule 4 of the Companies (Indian Accounting Standards) Rules, 2015, Reconciliation of Profit and Loss and Reconciliation of Equity does not apply to the company and hence not reported.

3 Segment Reporting : The company is in the business of distribution of pharmaceutical items. Therefore disclosures under Accounting Standard 17- Primary Segment Reporting is not applicable. Secondary segmental reporting on the basis of the geographical location of the customers is as below :

Sr.No	Particulars	Half year ended on		Year ended on	
		September 30, 2025	March 31, 2025	September 30, 2024	March 31, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	India	6629.12	8118.22	8716.28	16834.49
2	South Asian Countries	-	-	-	-
3	Rest of the World	-	-	-	-
	Total	6629.12	8118.22	8716.28	16834.49

4. The financial Results have been prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.

5. The Company has not paid the Income Tax liabilities of Rs. 43.72 lakhs for A.Y. 2024-2025 and Rs. 83.95 lakhs for 2025-26 of lakhs. However the provision has been made along-with the interest. The management is working on improving the cash flow management to ensure such non-compliance does not occur in future.

6. The above financial results are available on the website of the company i.e. www.monopharmacare Ltd. com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com

7. Figures for previous half year/ year have been regrouped wherever necessary.

For and on behalf of the Board of Directors
Mono Pharmacare Limited

Panilam S. Lakhtaria
Chairman & Managing Director

DIN: 07659275

Date: November 28, 2025

Place: Ahmedabad

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com

Consolidated Statement of Assets and Liabilities

(Rs. in Lakhs)

	Particulars	As at September 30th, 2025 (Unaudited)	As at 31st March, 2025 (Audited)
I.	EQUITY AND LIABILITIES		
(1)	Shareholders' Funds		
	(a) Share Capital	1766.86	1766.86
	(b) Reserve and surplus	1355.12	1353.06
	Minority Interest	3.64	3.52
		3125.62	3123.43
(2)	Non-current liabilities		
	(a) Long -term borrowings	2643.85	2596.14
	(b) Long -term Provisions	10.55	8.38
		2654.40	2604.52
(3)	Current Liabilities		
	(a) Short Term Borrowings	2855.73	2759.88
	(b) Trade Payables	2847.79	1879.83
	(c) Other Current Liabilities	354.46	482.20
	(d) Short- term Provisions	95.70	155.62
		6153.68	5277.55
	TOTAL EQUITY AND LIABILITIES	11933.70	11005.50
II.	ASSETS		
(1)	Non Current Assets		
	(a) Property, Plants & Equipment		
	(i) Tangible Assets	92.75	98.21
	(ii) Intangible Assets	0.87	1.00
	(iii) WIP	1.80	1.80
	(b) Non-Current Investments	-	-
	(c) Deferred tax assets (Net)	5.39	4.47
	(d) Long-term loans and advances	1.30	1.30
		102.11	106.77
(2)	Current Assets		
	(a) Inventories	5160.76	5538.61
	(b) Trade Receivables	6098.53	4188.75
	(c) Cash and Cash Equivalents	123.95	69.76
	(d) Short Term Loans and Advances	413.86	1013.92
	(e) Other Current Assets	34.49	87.68
		11831.59	10898.73
	TOTAL ASSETS	11933.70	11005.50

For and on behalf of the Board of Directors

Mono Pharmacare Limited

Panilam S. Lakhatariya

Chairman & Managing Director

DIN: 07659275

Date: November 28, 2025

Place: Ahmedabad

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com

Consolidated Cash Flow statement for the period ended on September 30, 2025**(Rs. in Lakhs)**

Particulars	September 30, 2025	March 31, 2025
Cash flow from operating activities		
Profit/(loss) before tax	12.14	446.29
Non-cash adjustments to reconcile profit before tax to net cash flows		
Depreciation	5.79	12.87
Finance Cost	160.57	402.55
Operating profit/(loss) before working capital changes	178.51	861.71
Movements in working capital:		
Increase/(decrease) in trade payables	967.95	911.32
Increase/(decrease) in other current liabilities	-127.74	362.86
Increase/(decrease) in short term provision	-59.92	93.37
Increase/(decrease) in short term borrowings	95.84	328.34
Decrease/(increase) in Inventories	377.85	-1309.35
Decrease/(increase) in trade receivables	-1909.78	-1029.72
Decrease/(increase) in short-term loans and advances	600.06	-542.43
Decrease/(increase) in other Current Assets	53.19	32.63
Cash generated from Operations	175.96	-291.27
Less: Direct taxes paid	-10.88	-139.00
Net Cash from Operating Activities (A)	165.08	-430.27
Cash flows from investing activities		
Sale/(Purchase) of Fixed Assets	-0.21	-22.63
Purchase of Investment	-	-
Net cash flow from/(used in) investing activities (B)	-0.21	-22.63
Cash flow from financing activities		
Acceptance / (Repayment) of Long Term Loan	47.71	883.66
Payment / (Repayment) of Long term Loan advance	-	1.20
Long term Provision	2.17	4.09
Proceeds from issue of equity shares	-	-
Securities Premium on Allotment of Equity Shares	-	-
Finance Cost	-160.57	-402.55
Net cash flow from/(used in) financing activities (C)	-110.69	486.39
Net increase/(decrease) in cash and cash equivalents (A+B+C)	54.18	33.49
Cash and cash equivalents at the beginning of the year	69.76	36.27
Cash and cash equivalents at the end of the year	123.95	69.76
Net increase/(decrease) in cash and cash equivalents	54.18	33.49

For and on behalf of the Board of Directors
Mono Pharmacare Limited


Panilam S. Lakhtariya
Chairman & Managing Director

DIN: 07659275

Date: November 28, 2025

Place: Ahmedabad

MONO PHARMACARE LIMITED

CIN:- L24304GJ2022PLC136193

Address:- 1A, Krinkal Appartment Opp. Mahalaxmi Temple, Paldi,
Ahmedabad-380007, Gujarat, India.

Email Id- info@monopharmacareltd.com

											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit committee (see Note 6a)	Value of transaction during the reporting period (see Note 6b)	In case monies are due to either party as a result of the transaction (see Note 1)		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
1.	Mono Pharmacare Limited	AAQCM2821E	Supal Distributors LLP - P	ADEFS8542E	Subsidiaries	Purchase of goods or services	500000000	374573.00	53387.00	15523677.02								
2.	Mono Pharmacare Limited	AAQCM2821E	Supal Distributors LLP - S	ADEFS8542E	Subsidiaries	Sale of goods or services	500000000	15092364.00	3595136.10	9222742.70								
3.	Mono Pharmacare Limited	AAQCM2821E	Ahmedabad Medical Corporation (P)	AAGFA0999L	Subsidiaries	Purchase of goods or services	500000000	23742513.00	22505471.10	-5763775.90								
4.	Mono Pharmacare Limited	AAQCM2821E	Ahmedabad Medical Corporation (S)	AAGFA0999L	Subsidiaries	Sale of goods or services	500000000	0.00	-2963322.00	0.00								
5.	Mono Pharmacare Limited	AAQCM2821E	Supal Pharma (p)	ADVFS4838G	Group companies	Purchase of goods or services	500000000	0.00	176272.00	600000.00								
6.	Mono Pharmacare Limited	AAQCM2821E	Supal Pharma (s)	ADVFS4838G	Group companies	Sale of goods or services	500000000	0.00	276477.00	489520.08								
7.	Mono Pharmacare Limited	AAQCM2821E	Supal Pharmacare Ltd (p)	ABLCS2611J	Group companies	Purchase of goods or services	500000000	3359516.00	4557421.00	12251256.30								
8.	Mono	AAQCM2821E	Supal	ABLCS2611J	Group	Sale of goods	500000000	10866438.0	-	2020199.00								

MONO PHARMACARE LIMITED

CIN:- L24304GJ2022PLC136193

Address:- 1A, Krinkal Appartment Opp. Mahalaxmi Temple, Paldi,
Ahmedabad-380007, Gujarat, India.

Email Id- info@monopharmacareltd.com

	Pharmacare Limited	821E	Pharmacare Ltd (S)		companies	or services		0	3697905.00									
9.	Mono Pharmacare Limited	AAQCM2821E	Supal Trading LLC	NA	Group companies	Sale of goods or services	500000000	0.00	841386.00	841386.00								
10.	Mono Pharmacare Limited	AAQCM2821E	Panilam Shivilal Lakhatariya	ACDPL7362D	Directors	Remuneration	-	400000.00	200000.00	561200.00								
11.	Mono Pharmacare Limited	AAQCM2821E	Panilam Shivilal Lakhatariya	ACDPL7362D	Directors	Loan	-	30166163.00	80718991.60	101201922.60								
12.	Mono Pharmacare Limited	AAQCM2821E	Supal Panilam Lakhatariya	AHZPL5982C	Directors	Remuneration	-	400000.00	200000.00	561200.00								
13.	Mono Pharmacare Limited	AAQCM2821E	Supal Panilam Lakhatariya	AHZPL5982C	Directors	Loan	-	2938138.00	25632940.25	24280462.25								
14.	Mono Pharmacare Limited	AAQCM2821E	Archit Shah Current Capital	CFNPS2084C	Directors	Remuneration	-	85742.00	78600.00	255800.00								
Total (of Note 6b)								87425447	132174855.05	162045590.05								

Notes:

1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.

MONO PHARMACARE LIMITED

CIN:- L24304GJ2022PLC136193

Address:- 1A, Krinkal Appartment Opp. Mahalaxmi Temple, Paldi,
Ahmedabad-380007, Gujarat, India.

Email Id- info@monopharmacareltd.com

5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
6. In case of a multi-year related party transaction:
 - a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
 - b. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
7. "Cost" refers to the cost of borrowed funds for the listed entity.
8. PAN will not be displayed on the website of the Stock Exchange(s).
9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.

For and on Behalf of
Mono Pharmacare Limited,

Mr, Panilam Lakhatariya
Managing Director
DIN: 07659275